Roxane Dilcher, Stephan Wall, Mattes Groß, Sabrina Katzdobler, Olivia Wagemann, Carla Palleis, Endy Weidinger, Urban Fietzek, Alexander Bernhardt, Carolin Kurz, Christian Ferschmann, Maximilian Scheifele, Mirlind Zaganjori, Johannes Gnörich, Katharina Bürger, Daniel Janowitz, Boris-Stephan Rauchmann, Sophia Stöcklein, Peter Bartenstein, Victor Villemagne, John Seibyl, Osama Sabri, Henryk Barthel, Robert Perneczky, Florian Schöberl, Andreas Zwergal, Günter U. Höglinger, Johannes Levin, Nicolai Franzmeier, Matthias Brendel
{"title":"Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies","authors":"Roxane Dilcher, Stephan Wall, Mattes Groß, Sabrina Katzdobler, Olivia Wagemann, Carla Palleis, Endy Weidinger, Urban Fietzek, Alexander Bernhardt, Carolin Kurz, Christian Ferschmann, Maximilian Scheifele, Mirlind Zaganjori, Johannes Gnörich, Katharina Bürger, Daniel Janowitz, Boris-Stephan Rauchmann, Sophia Stöcklein, Peter Bartenstein, Victor Villemagne, John Seibyl, Osama Sabri, Henryk Barthel, Robert Perneczky, Florian Schöberl, Andreas Zwergal, Günter U. Höglinger, Johannes Levin, Nicolai Franzmeier, Matthias Brendel","doi":"10.1002/alz.14185","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We cross-sectionally assessed combinations of cerebrospinal fluid measures (CSF p-tau<sub>181</sub> and t-tau) and <sup>18</sup>F-PI-2620 tau-positron emission tomography (PET) in patients with AD (<i>n</i> = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, <i>n</i> = 82) and healthy controls (<i>n</i> = 19).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Elevated CSF p-tau<sub>181</sub> and cortical <sup>18</sup>F-PI-2620 binding was characteristic for AD while normal CSF p-tau<sub>181</sub> with elevated subcortical <sup>18</sup>F-PI-2620 binding was characteristic for 4RTs. <sup>18</sup>F-PI-2620-assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>The specific combination of CSF markers and <sup>18</sup>F-PI-2620 tau-PET in disease-specific regions facilitates the biomarker-guided stratification of AD and 4RTs. This has implications for biomarker-aided diagnostic workflows and the advancement in clinical trials.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Novel biomarker-based algorithm for differentiating AD and 4R-tauopathies.</li>\n \n <li>A combination of CSF p-tau<sub>181</sub> and <sup>18</sup>F-PI-2620 discriminates AD versus 4R tauopathies.</li>\n \n <li>Hypoperfusion serves as an additional neuronal injury biomarker in AD.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":null,"pages":null},"PeriodicalIF":13.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14185","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14185","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.
METHODS
We cross-sectionally assessed combinations of cerebrospinal fluid measures (CSF p-tau181 and t-tau) and 18F-PI-2620 tau-positron emission tomography (PET) in patients with AD (n = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, n = 82) and healthy controls (n = 19).
RESULTS
Elevated CSF p-tau181 and cortical 18F-PI-2620 binding was characteristic for AD while normal CSF p-tau181 with elevated subcortical 18F-PI-2620 binding was characteristic for 4RTs. 18F-PI-2620-assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD.
DISCUSSION
The specific combination of CSF markers and 18F-PI-2620 tau-PET in disease-specific regions facilitates the biomarker-guided stratification of AD and 4RTs. This has implications for biomarker-aided diagnostic workflows and the advancement in clinical trials.
Highlights
Novel biomarker-based algorithm for differentiating AD and 4R-tauopathies.
A combination of CSF p-tau181 and 18F-PI-2620 discriminates AD versus 4R tauopathies.
Hypoperfusion serves as an additional neuronal injury biomarker in AD.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
